Diagnostic and treatment costs of patients diagnosed or suspected of COVID-19 disease in eastern Iran

Document Type : Original article

Authors

1 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

2 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran

Abstract

Background and Aims: To understand the social and individual effects of the disease and to decide on the allocation of health resources, it is necessary to recognize the economic burden of coronary heart disease (COVID-19). However, there is limited data in this area. The aim of this study was to estimate the diagnostic and treatment costs of patients with or suspected of having Covid-19 disease admitted to hospitals in Eastern Iran.
Materials and Methods: This descriptive and analytical retrospective study was performed using data collected from 2980 patients admitted to 30 hospitals from February 2020 to April 2021 in Iran. To collect the data, a suitable data collection tool was designed to record the details of resource usage. A multivariate regression analysis was performed to examine the relationship between treatment costs and socio-demographic, disease severity, and underlying diseases. Data were analyzed using Excel 2017 software and SPSS version 21 .
Results: The cost of hospitalization per patient was 5433500 Rials, of which 74% was paid by social health insurance systems, 19% by the government and 7% by patients. The largest components were the cost of hoteling (37%) and medicine (36%). The 4 subscales predicted age, sex, underlying disease, and severity of 48.6% of the cost variance.
Conclusion: Understanding the economic consequences of diseases can help policymakers in planning to reduce out-of-pocket payments and planning for financing. Since Covid-19 is an emerging disease and there is no definitive cure for it,discovering an effective drug may change medical costs and reduce the length of hospital stay, thus significantly reducing treatment costs.

Keywords

References

[1]           Rice DPJAJoPH, Health tN. Estimating the cost of illness. 1967;57(3):424-40.
[2]           Shankar S, Boyanagari M, Boyanagari VK, Shankar M, Ayyanar RSJCE, Health G. Profile of breast cancer patients receiving government sponsored free treatment and the associated economic costs. 2018;6(4):203-7.
[3]           McKibbin W, Fernando RJAEP. The global macroeconomic impacts of COVID-19: Seven scenarios. 2021;20(2):1-30.
[4]           Fernandes NJAaS. Economic effects of coronavirus outbreak (COVID-19) on the world economy. 2020.
[5]           Makridis C, Hartley JJSEPB. The cost of covid-19: A rough estimate of the 2020 us gdp impact. 2020.
[6]           Organization WH. Coronavirus disease 2019 (‎ COVID-19)‎: situation report, 94. 2020.
[7]           Nguyen HC, Nguyen MH, Do BN, Tran CQ, Nguyen TT, Pham KM, et al. People with suspected COVID-19 symptoms were more likely depressed and had lower health-related quality of life: the potential benefit of health literacy. 2020;9(4):965.
[8]           Moradzadeh RJE, Infection. The challenges and considerations of community-based preparedness at the onset of COVID-19 outbreak in Iran, 2020. 2020;148.
[9]           Nayeri ND, Taghavi T, Shali MJBJ. Ethical challenges in the care of emerging diseases: A systematic literature review. 2017;7:85-96.
[10]        Arabi YM, Murthy S, Webb SJIcm. COVID-19: a novel coronavirus and a novel challenge for critical care. 2020;46(5):833-6.
[11]        Huo X, Chen L-L, Hong L, Xiang L-H, Tang F-Y, Chen S-H, et al. Economic burden and its associated factors of hospitalized patients infected with A (H7N9) virus: a retrospective study in Eastern China, 2013–2014. 2016;5(1):1-8.
[12]        Rootman I, Goodstadt M. Evaluation in health promotion: principles and perspectives: WHO Regional Office Europe; 2001.
[13]        Bartsch SM, Ferguson MC, McKinnell JA, O'shea KJ, Wedlock PT, Siegmund SS, et al. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States: A simulation estimate of the direct medical costs and health care resource use associated with COVID-19 infections in the United States. 2020;39(6):927-35.
[14]        Lee GM, Lett S, Schauer S, LeBaron C, Murphy TV, Rusinak D, et al. Societal costs and morbidity of pertussis in adolescents and adults. 2004;39(11):1572-80.
[15]        Xiao F, Chen B, Wu Y, Wang Y, Han DJZlxbxzzZlz. Analysis on the cost and its related factors of clinically confirmeds severe acute respiratory syndrome cases in Beijing. 2004;25(4):312-6.
[16]        Zhou L, Situ S, Huang T, Hu S, Wang X, Zhu X, et al. Direct medical cost of influenza-related hospitalizations among severe acute respiratory infections cases in three provinces in China. 2013;8(5):e63788.
 
Navid No
Volume 25, Issue 82
September 2022
Pages 27-37

Files

Share

How to cite

Statistics